Glukokortikoid-induzierte Osteoporose – Fokus Therapie (Teil 1)

Buttgereit F (2020) Views on glucocorticoid therapy in rheumatology: the age of convergence. Nat Rev Rheumatol 16:239–246 Briot K, Roux C (2014) Glucocorticoid-induced osteoporosis. RMD Open. https://doi.org/10.1136/rmdopen-2014-000014 Soucy E, Bellamy N, Adachi JD et al (2000) A canadian survey on the management of corticosteroid induced osteoporosis by rheumatologists. J Rheumatol 27:1506–1512 Fardet L, Petersen I, Nazareth I (2011) Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology 50:1982–1990 Overman RA, Yeh JY, Deal CL (2013) Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res 65:294–298 Diez-Perez A, Hooven FH, Adachi JD et al (2011) Regional differences in the treatment of osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 49:493–498 Silvermann S, Curtis J, Saag K et al (2015) International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. Osteoporos Int 26:419–420 Van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787 Angeli A, Guglielmi G, Dovio A et al (2006) High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39:253–259 Amiche MA, Abtahi S, Driessen JHM et al (2018) Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a polulation-based case-control study. Arch Osteoporos 13:30. https://doi.org/10.1007/s11657-018-0424-x Balasubramanian A, Wade SW, Adler RA et al (2016) Glucorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int 27:3239–3249 Van Staa TP, Leufkens HG, Abenhaim L et al (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000 Oelzner P, Schwabe A, Lehmann G et al (2008) Significance of risk factors for osteoporosis is dependent on gender and menopause in rheumatoid arthritis. Rheumatol Int 28:143–150 Henneicke H, Gasparini SJ, Brennan-Speranza TC et al (2014) Glucocorticoids and bone. Trends Endocrinol Metab 25:197–211 Adami G, Saag KG (2019) Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int 30:1145–1156 Delgado-Calle J, Sato AY, Bellido T (2017) Role and mechanism of action of sclerostin in bone. Bone 96:29–37 Ducy P, Amling MN, Takeda S et al (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197–207 Fain JN (2013) Impact of glucocorticoid hormones on adipokine secretion and human adipose tissue metabolism. Horm Mol Biol Clin Investig 14:25–32 Ferron M, Lacombe J (2014) Regulation of energy metabolism by the skleleton: osteocalcin and beyond. Arch Biochem Biophys 561:137–146 Kalpakcioglu BB, Engelke K, Genant HK (2011) Advanced imaging assessment of bone fragility in glucocorticoid-induced osteoporosis. Bone 48:1221–1231 Buckley L, Guyatt G, Fink HA et al (2017) American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 69:1521–1537 AWMF (2017) Prophylaxe, Diagnostik und Therapie der Osteoporose. https://www.awmf.org/upload/xszleitlinien/283-001IS3Osteoporose-Prophylaxe-Diagnostik-Therapie Vasile M, Corinaldesi C, Antinozzi C et al (2017) Vitamin D in autoimmune rheumatic diseases: a view inside gender differences. Pharmacol Res 117:228–241 Bischoff-Ferrari HA, Willett WC, Orav EJ et al (2012) A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 367:40–49 Fanouriakis A, Kostopoulou M, Cheema K et al (2020) 2019 update of the joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79:713–723 Dörner T, Furie R (2019) Novel paradigms in systemic lupus erythematosus. Lancet 393:2344–2358 Kohsaka H, Mimori T, Kanda T et al (2019) Treatment consensus for the management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. J Dermatol 46:1–18 Schirmer JH, Aries PM, de Groot K et al (2017) S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden. Z Rheumatol 76(Suppl):77–104 Groh M, Pagnoux C, Baldini C et al (2015) Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 26:545–553 Hellmich B, Agueda A, Monti S et al (2020) 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79:19–30 Schirmer JH, Aries PM, Balzer K et al (2020) S2k-Leitlinie: Management der Großgefäßvaskulitiden. Z Rheumatol 79(Suppl. 3):67–95 Buttgereit F, Brabant T, Dinges H et al (2018) S3-Leitlinie zur Behandlung der Polymyalgia rheumatica. Z Rheumatol 77:429–441 Fiehn C, Holle J, Iking-Konert C et al (2018) S2e-Leitlinie: Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten. Z Rheumatol 77(Suppl 2):S35–S53